TY - JOUR T1 - Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2 JF - medRxiv DO - 10.1101/2020.06.05.20122622 SP - 2020.06.05.20122622 AU - Russell M. Petrak AU - Nathan C. Skorodin AU - Nicholas W. Van Hise AU - Robert M. Fliegelman AU - Jonathan Pinsky AU - Vishal Didwania AU - Michael Anderson AU - Melina Diaz AU - Kairav Shah AU - Vishnu V. Chundi AU - David W. Hines AU - Brian P. Harting AU - Kamo Sidwha AU - Brian Yu AU - Paul Brune AU - Anjum Owaisi AU - David Beezhold AU - Joseph Kent AU - Dana Vais AU - Alice Han AU - Neethi Gowda AU - Nishi Sahgal AU - Jan Silverman AU - Jonathan Stake AU - Jenie Nepomuceno AU - Renuka Heddurshetti Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/08/2020.06.05.20122622.abstract N2 - Background Tocilizumab is an IL-6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with SARS-CoV-2.Methods We evaluated patients treated with tocilizumab for a SARS-CoV-2 infection who were admitted between 3/13/20 and 4/16/20. This was a multi-center study with data collected by chart review both retrospectively and concurrently. Parameters evaluated included age, sex, race, use of mechanical ventilation (MV), usage of steroids and vasopressors, inflammatory markers, and comorbidities. Early dosing was defined as a tocilizumab dose administered prior to or within one (1) day of intubation. Late dosing was defined as a dose administered greater than one (1) day after intubation. In the absence of mechanical ventilation, the timing of the dose was related to the patient’s date of admission only.Results We evaluated 145 patients. The average age was 58.1 years, 64% were male, 68.3% had comorbidities, and 60% received steroid therapy. Disposition of patients was 48.3% discharged and 29.3% expired, of which 43.9% were African American. Mechanical ventilation was required in 55.9%, of which 34.5% expired. Avoidance of MV (p value = 0.002) and increased survival (p value < 0.001) was statistically associated with early dosing.Conclusions Tocilizumab therapy was effective at decreasing mortality and should be instituted early in the management of critically ill COVID-19 patients.Summary Utilizing tocilizumab early in the treatment course of critically ill patients with COVID-19 resulted in significant decreases in mortality and the avoidance of mechanical ventilation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Western IRB considered this an exempt projectAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon request, we will make a de-identified dataset available ER -